ACULAR LS (ketorolac tromethamine) by AbbVie is anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. First approved in 2003.
Drug data last refreshed 8h ago · AI intelligence enriched 4d ago
Acular LS is a topical ophthalmic solution containing ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID) administered as eye drops. It works by inhibiting prostaglandin biosynthesis to reduce inflammation and pain in the eye. The product is indicated for post-operative ocular inflammation and other eye-related inflammatory conditions.
With LOE approaching in 1.4 years and minimal Medicare claims, Acular LS faces significant revenue decline; brand team focus is transitioning to defense and portfolio optimization rather than growth initiatives.
anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment
Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment
Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis
A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing
Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells
Worked on ACULAR LS at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
Working on Acular LS offers limited career growth potential given its imminent LOE and minimal commercial activity, but provides valuable experience in defensive marketing, patent strategy, and managed decline management. Professionals should view this role as a stepping stone focused on operational excellence and preparation for portfolio transitions rather than revenue growth and career acceleration.